Oncology Hematology Associates | Springfield, MO

Research site

(Unclaimed)

Location

3850 S. National Avenue, Suite 600, Springfield, Missouri, United States of America

Site insights

Top conditions

Top treatments

Etoposide

Durvalumab

Clindamycin

Zongertinib

AZD7442

Lenalidomide

Niraparib

duvelisib

REC-4881

Zanubrutinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 18 total trials

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling

Myelofibrosis

Drug: Imetelstat

Drug: Best Available Therapy (BAT)

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatmen...

Enrolling

Solid Tumor

APC Gene Mutation

Drug: REC-4881

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with...

Enrolling

Relapsed/Refractory Follicular Lymphoma

Marginal Zone Lymphoma

Drug: Rituximab

Drug: Lenalidomide

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve U...

Enrolling

Melanoma

Drug: ABP 206

Drug: Nivolumab

Locations recently updated

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumour...

Enrolling

Lung Cancer, Non-squamous, Non-small Cell

Drug: carboplatin

Drug: pemetrexed

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 derm...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Chlorhexidine

Drug: Clindamycin

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO)

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors an...

Active, not recruiting

Solid Tumor

Locally Advanced Solid Tumor

Drug: Niraparib

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting

Solid Tumor

Malignant Neoplasm

Drug: nab-sirolimus

Locations recently updated

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...

Enrolling

Small-Cell Lung Cancer

Extensive-Stage Small-Cell Lung Cancer

Drug: Tarlatamab

Drug: Durvalumab

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

Active, not recruiting

Chemotherapy-induced Thrombocytopenia

Other: Placebo

Biological: Romiplostim

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or br...

Enrolling

Chemotherapy-induced Thrombocytopenia

Drug: Placebo

Drug: Romiplostim

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in...

Enrolling

Extensive Stage Small Cell Lung Cancer

Drug: Serplulimab + chemotherapy (carboplatin-etoposide)

Drug: Atezolizumab + chemotherapy (carboplatin-etoposide)